Table 1.
Primary Tumor | n (%) |
---|---|
Lung | 89 (44.7%) |
NSCLC | 75 (37.9%) |
SCLC | 12 (6.1%) |
Mamma | 23 (11.6%) |
ER+ | 4 (2%) |
HER2+ | 7 (3.5%) |
ER+/HER2+ | 3 (1.5%) |
Triple- | 8 (4%) |
RCC | 5 (2.5%) |
Colon | 8 (4%) |
CUP | 6 (3%) |
Other | 41 (20.6%) |
Primary Tumor | n (%) |
---|---|
Lung | 89 (44.7%) |
NSCLC | 75 (37.9%) |
SCLC | 12 (6.1%) |
Mamma | 23 (11.6%) |
ER+ | 4 (2%) |
HER2+ | 7 (3.5%) |
ER+/HER2+ | 3 (1.5%) |
Triple- | 8 (4%) |
RCC | 5 (2.5%) |
Colon | 8 (4%) |
CUP | 6 (3%) |
Other | 41 (20.6%) |